Clinical Efficacy of Soliris Supported by Pharmacological Analysis

An analysis of pharmacological data supports the observed clinical efficacy of Soliris (eculizumab) in significantly reducing relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) given the therapy in the PREVENT Phase 3 clinical trial. At its approved dose, Soliris led to rapid, sustained, and complete suppression…

#AANAM – Soliris Has Long-term Relapse Prevention

Soliris (eculizumab) significantly reduced the risk of disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD) over nearly three years, according to new data from the clinical trial PREVENT and its extension study. Additional findings project that long-term Soliris treatment may reduce relapse risk over the course of…

#MDA2021 – Soliris Did Not Increase Infection Risk in NMOSD, Trials Show

Treatment with Soliris (eculizumab) does not increase the risk of infections or serious infections among people with neuromyelitis optica spectrum disorder (NMOSD) and antibodies against the protein aquaporin-4 (AQP4), even in those receiving accompanying immunosuppressive therapies. Those were the findings from a post hoc analysis of…

Autoimmune Marker CH50 May Be Useful Measure of Soliris Efficacy

The autoimmune biomarker CH50 was directly impacted by treatment with Soliris (eculizumab) in three people with neuromyelitis optica spectrum disorder (NMOSD), a case report has shown. According to researchers, this suggests that CH50 may be a useful…